“Some people with OCD, they get stuck in that state where they become hyperaware of some part of their body, of some signal that they're getting in their brain,” says ADAA member Jon Hershfield, MA, LMFT in this Tonic article on rare symptoms of OCD.
"In phase 3 clinical trials, we saw this therapy provide sustained improvement to patients with treatment-resistant depression," says ADAA member Michael Thase, MD in this article about the FDA approval of the esketamine nasal spray.
“There is a lot of activity in this space, looking at drugs that work faster and work on different mechanisms completely than what has been studied before,” says ADAA member Sanjay Mathew, MD in this Fox Business article on the new FDA approval of Spravato.
“This is an exciting development and the first novel mechanism that goes beyond the current serotonin treatments,” says ADAA member Sanjay Mathew, MD in this Washington Times article on the FDA approval of Spravato.
On March 5, 2019 the FDA approved a new nasal spray medication- Spravato (esketamine) for treatment-resistant depression, available only at a certified doctor’s office or clinic.
Ketamine represents a major step forward in the treatment of depression and suicide prevention. ADAA recognizes that clinicians want to offer their patients evidence-based options which have passed through the numerous stages of FDA testing, and this marks the first FDA approval of a ketamine product for a psychiatric indication. This is also the first antidepressant with a novel mechanism of action that we have had in decades.
“Financial anxiety might come from worrying about getting more money into your bank account or wondering how you’re going to pay for your kids to go to college,” says ADAA member Debra Kissen, PhD, MHSA in this Reward Expert article on financial anxiety.
ADAA members Lata McGinn, PhD and Alec Miller, PsyD share their research team's article "Clinical Guidelines for Improving Dialectical Thinking in DBT," featured in the Cognitive and Behavioral Practice Journal.
Read this month's issue of Depression and Anxiety, ADAA's official online journal. The Journal welcomes original research and synthetic review articles covering neurobiology (genetics and neuroimaging), epidemiology, experimental psychopathology, and treatment (psychotherapeutic and pharmacologic) aspects of mood and anxiety disorders, and related phenomena in humans. This month's issue focuses on depression and anxiety.
ADAA is an international nonprofit organization dedicated to the prevention, treatment, and cure of anxiety, depressive, obsessive-compulsive, and trauma-related disorders through education, practice, and research.